Results 181 to 190 of about 9,722 (255)

Poly(ADP-ribose)polymerases (PARP) signalling of Topo I-dependent DNA damage

, 2009
Piera Quesada, Domenico Fulgione, Filomena Tramontano, Valeria Maselli, Maria Malanga, Giovanna D’Onofrio   +5 more
core  

Poly [ADP-Ribose] Polymerase 1 [PDF]

, 2020
openaire   +1 more source

NAD⁺ metabolism at the host-virus interface. [PDF]

J Gen Virol
Jhandai P, Vaddadi K, Liu L.
europepmc   +1 more source

Poly [ADP-Ribose] Polymerase 2 [PDF]

, 2020
openaire   +1 more source

Poly [ADP-Ribose] Polymerase 3 [PDF]

, 2020
openaire   +1 more source

SLFN11 expression as a marker of small cell lung cancer vulnerability to combined PARP inhibitors and immune checkpoint inhibitors during maintenance. [PDF]

J Thorac Dis
Pujol JL.
europepmc   +1 more source

Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle. [PDF]

Cell Metab, 2014
Pirinen E, Cantó C, Jo YS, Morato L, Zhang H, Menzies KJ, Williams EG, Mouchiroud L, Moullan N, Hagberg C, Li W, Timmers S, Imhof R, Verbeek J, Pujol A, van Loon B, Viscomi C, Zeviani M, Schrauwen P, Sauve AA, Schoonjans K, Auwerx J.   +21 more
europepmc   +1 more source

PARP1 as a novel therapeutic and diagnostic tool in autoimmune rheumatic diseases: a systematic literature review. [PDF]

Rheumatol Int
Dey M, Dey M.
europepmc   +1 more source

Poly (ADP-Ribose) Polymerase Inhibitor [PDF]

, 2020
openaire   +1 more source

PARP (poly[ADP-ribose] polymerase) [PDF]

, 2008
openaire   +2 more sources